SILVER SPRING, Md., Aug. 9, 2012 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology provider of cell and gene therapy solutions, announced today an article describing cancer treatments under development by its wholly-owned subsidiary, Austrianova Singapore, has just been published in BioSpectrum Asia, the leading biotechnology industry magazine in Asia. The invited article entitled " 'Suicide genes' is the next step to cure cancer" was co-authored by Dr. Brian Salmons, Austrianova's President and CEO, and Dr. Walter Gunzburg, its Chairman. The article featured the Company's patented live cell encapsulation technology and pointed to the clinical success in the treatment of solid tumors, among other uses. The use of live encapsulated cells that locally catalyzed conversion of chemotherapeutic prodrugs to their active, cancer-killing forms at the site where they are needed was discussed since it has been shown to work well for pancreatic cancer. In the completed Phase 1/2 clinical trial, patients were noted to experience a doubling of the median survival time through disease improvement or stabilization and an important reduction in the side effects of the added chemotherapy treatment was observed while at the same time enhancing their anti-tumor effectiveness. The safety and efficacy data obtained from clinical trials of the treatment of pancreatic and breast cancer solid tumors was reviewed in the article. In addition, there was also a discussion of additional preclinical data suggesting improved clinical benefits with fewer side effects than standard chemotherapy were also achievable for tumors such as hepatocellular (liver) cancer, squamous cell carcinoma, ovarian cancer, colon cancer metastases and possibly even brain tumors like glioma/glioblastoma. Promising preclinical data has already demonstrated use of multiple prodrug activation systems. The data from this ongoing research offers the possibility of "personalized" therapies. There is even the possibility of combining these treatments with standard radiotherapy to have a greater effect and potential increased success in treating cancer patients. The article also points out that encapsulated cells can also be used to attack tumors by placing them in the body and allowing continuous production of tumor-honing toxic antibodies, such as Herceptin®. Another means to attack cancer cells can be by placing into the body encapsulated living cells that excrete natural growth inhibitors like tumor necrosis factors (proteins that cause certain cells to die) or anti-angiogenic factors (proteins that inhibit new blood vessel formation). All of these antitumor strategies represent an arsenal that can be combined to attack cancer at many different levels.